男性性腺機能低下症:パイプラインレビュー2019下半期

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GDATA9120325)
◆英語タイトル:Male Hypogonadism - Pipeline Review, H2 2019
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GDATA9120325
◆発行日:2019年11月
◆調査対象地域:グローバル
◆産業分野:製薬及び医療
◆ページ数:103
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[男性性腺機能低下症:パイプラインレビュー2019下半期]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

Male Hypogonadism – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Male Hypogonadism – Pipeline Review, H2 2019, provides an overview of the Male Hypogonadism (Male Health) pipeline landscape.

Male hypogonadism is a condition in which the body doesn’t produce enough testosterone. Symptoms include fatigue, hot flashes, infertility, decrease in muscle mass and loss of bone mass (osteoporosis). Risk factors for hypogonadism include HIV/AIDS, Klinefelter syndrome, Kallmann syndrome, injury to testicles and untreated sleep apnea. Treatment includes hormone replacement.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Male Hypogonadism – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Male Hypogonadism (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Male Hypogonadism (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 3, 7, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Male Hypogonadism (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Male Hypogonadism (Male Health).
- The pipeline guide reviews pipeline therapeutics for Male Hypogonadism (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Male Hypogonadism (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Male Hypogonadism (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Male Hypogonadism (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Male Hypogonadism (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Male Hypogonadism (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Male Hypogonadism – Overview
Male Hypogonadism – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Male Hypogonadism – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Male Hypogonadism – Companies Involved in Therapeutics Development
Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd
Male Hypogonadism – Drug Profiles
chorionic gonadotropin ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corifollitropin alfa – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
enclomiphene citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IAS-167A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kisspeptin-10 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leflutrozole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
leuprolide acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Libidua – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LPCN-1111 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Block VDAC1 for Hypogonadism – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rifene – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone propionate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
testosterone undecanoate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VERU-722 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Male Hypogonadism – Dormant Projects
Male Hypogonadism – Discontinued Products
Male Hypogonadism – Product Development Milestones
Featured News & Press Releases
Nov 01, 2019: Acerus provides update on temporary unavailability of NATESTO in Canada and South Korea
Oct 23, 2019: Acerus Pharma hosting key opinion leader meeting on unique clinical evidence of NATESTO for treatment of Hypogonadism
Oct 17, 2019: New data demonstrates that Natesto increases serum testosterone and improves symptoms while maintaining normal semen parameters in men with low testosterone through six months
Oct 16, 2019: Aytu BioScience to announce results from Natesto spermatogenesis study on Thursday, October 17
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Male Hypogonadism, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Male Hypogonadism - Pipeline by Allergan Plc, H2 2019
Male Hypogonadism - Pipeline by Diurnal Group Plc, H2 2019
Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2019
Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2019
Male Hypogonadism - Pipeline by Lipocine Inc, H2 2019
Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2019
Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2019
Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2019
Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2019
Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2019
Male Hypogonadism - Pipeline by Viramal Ltd, H2 2019
Male Hypogonadism - Dormant Projects, H2 2019
Male Hypogonadism - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Male Hypogonadism, H2 2019 9
Number of Products under Development by Companies, H2 2019 10
Number of Products by Targets, H2 2019 16
Number of Products by Stage and Targets, H2 2019 16
Number of Products by Mechanism of Actions, H2 2019 18
Number of Products by Stage and Mechanism of Actions, H2 2019 18
Number of Products by Routes of Administration, H2 2019 20
Number of Products by Stage and Routes of Administration, H2 2019 20
Number of Products by Molecule Types, H2 2019 22
Number of Products by Stage and Molecule Types, H2 2019 22

*** 掲載企業 ***

Allergan Plc
Diurnal Group Plc
EndoCeutics Inc
Ferring International Center SA
Lipocine Inc
M et P Pharma AG
Medlab Clinical Ltd
Merck & Co Inc
Mereo Biopharma Group Plc
TesoRx Pharma LLC
Viramal Ltd

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • ポリ塩化アルミニウム・塩化カルシウムの世界市場2018
    Polyaluminium Calcium Chloride Report by Material, Application, and Geography – Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United …
  • ファン空気弁の世界市場:販売動向2017
    Notes:Sales, means the sales volume of Fan Air Valve Revenue, means the sales value of Fan Air Valve This report studies sales (consumption) of Fan Air Valve in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, …
  • 山羊乳乳児食の世界市場:メーカー別、地域別、種類別、用途別、市場予測(~2023)
    Goat Milk Infant Formula, aslo known as breast milk of goat milk formula. It is a manufactured food designed and marketed with fresh goat's milk as the main raw material for feeding to babies and infants, usually prepared for bottle-feeding or cup-feeding from goat milk powder (mixed with water) or …
  • 世界の木質系バイオマス燃焼ボイラ市場2017
    Notes:Sales, means the sales volume of Woody Biomass Boiler Revenue, means the sales value of Woody Biomass Boiler This report studies sales (consumption) of Woody Biomass Boiler in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries …
  • 食用油の世界市場
    In this report, the global Edible Oil market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (milli …
  • 工業用過酸化水素の世界市場予測2018-2023
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Industrial Hydrogen Peroxide market for 2018-2023. Hydrogen peroxide is a chemical compound with the formula H2O2. In its pure form, it is a pale blue, clear liquid, slightly …
  • クロロぎ酸イソブチルの世界市場:販売動向2017
    Notes:Sales, means the sales volume of Isopropyl Chloroformate Revenue, means the sales value of Isopropyl Chloroformate This report studies sales (consumption) of Isopropyl Chloroformate in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/ …
  • MOST/イーサネットの世界市場:販売動向2017
    Notes:Sales, means the sales volume of In-Vehicle Media Oriented Systems Transport(MOST)/Ethernet Revenue, means the sales value of In-Vehicle Media Oriented Systems Transport(MOST)/Ethernet This report studies sales (consumption) of In-Vehicle Media Oriented Systems Transport(MOST)/Ethernet in Glob …
  • ジメチルカルバミン酸クロライドの世界市場2019
    The Global Dimethylcarbamoylchloride (CAS 79-44-7) Industry 2019 Market Research Report is a professional and in-depth study on the current state of the Dimethylcarbamoylchloride industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applicati …
  • SPECT放射性医薬品の世界市場
    In this report, the global SPECT Radiopharmaceuticals market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025. Geographically, this report is segmented into several key Regions, with production, consumption …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GDATA9120325 )"男性性腺機能低下症:パイプラインレビュー2019下半期" (英文:Male Hypogonadism - Pipeline Review, H2 2019)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。